目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中活化的B细胞相关蛋白MUM1的表达与临床病理特征之间的关系。方法利用组织微阵列免疫组化检测60例DLBCL石蜡包埋组织中MUM1、bcl-6和CD10的表达。结果60例DLBCL被分为...目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中活化的B细胞相关蛋白MUM1的表达与临床病理特征之间的关系。方法利用组织微阵列免疫组化检测60例DLBCL石蜡包埋组织中MUM1、bcl-6和CD10的表达。结果60例DLBCL被分为两种抗原表达表型:一种为活化的B细胞表型(A型)表达MUM1;另一种为生发中心B细胞表型(B型),表达CD10和(或)bcl-6但不表达MUM1。60例DLBCL中61.67%为A型,31.67%为B型,其中59.25%中心母细胞型,3/4免疫母细胞型,2/2间变性大B细胞型均为A型。A型在结外和结内DLBCL中分别占61.76%和61.54%,而在胃肠道DLBCL中的比例(47%)显著低于在其他结外DLBCL中的比例(80%,P=0.079)。在MUM-1(+)/bcl-6(+)/CD10(+/-)的病例中,75.00%(12/16)为结外DLBCL,高于在MUM-1(+)/bcl-6(-)/CD10(-)病例中的比例43.75%(7/16),但差异没有显著性(P=0.149)。结论A型(表达MUM1)在DLBCL中的比例较高,提示MUM1表达很可能与DLBCL组织学变异有关,联合检测CD10和bcl-6,可协助DLBCL分型诊断。展开更多
目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结...目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结果bcl-2、bcl-6、CD10、MUM1在60例弥漫性大B细胞淋巴瘤中的表达率分别为55.0%(33/60)、48.3%(29/60)、46.7%(28/60)、58.3%(35/60),其中GCB占55.0%(33/60),non-GCB占45.0%(27/60)。GCB、non-GCB中bcl-2的表达差异具有显著性。在non-GCB中,bcl-6+与bcl-6-的病例bcl-2表达的差异具有显著性。结论该组病例GCB所占的比率超过non-GCB,bcl-2在DLBCL亚分类中可能具有一定的作用。展开更多
弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细...弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细胞,具有侵袭性临床表现,需要高效力化疗的一组恶性淋巴瘤,这类肿瘤发生于淋巴结内或结外,可原发或继发于其他低度恶性淋巴瘤的演进[4].展开更多
目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中CD10、BCL-6和MUM1的表达及临床病理意义。方法对60例弥漫大B细胞淋巴瘤标本行HE和免疫组化染色观察,并复习文献。结果 60例DLBCL中CD10、BCL-6和MUM1的阳性表达率分...目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中CD10、BCL-6和MUM1的表达及临床病理意义。方法对60例弥漫大B细胞淋巴瘤标本行HE和免疫组化染色观察,并复习文献。结果 60例DLBCL中CD10、BCL-6和MUM1的阳性表达率分别为16.67%(10/60)、46.67%(28/60)和70.17%(43/60)。其中生发中心型(GCB)9例(15%),非生发中心型(non-GCB)51例(85%)。CD10、BCL-6和MUM1在生发中心亚型和非生发中心亚型中的表达具有显著性差异(P<0.05)。结论 CD10、BCL-6和MUM1在DL-BCL亚型分类中具有重要意义,其表达对判断患者预后及指导临床治疗提供重要指标。展开更多
Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated seve...Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome. In this study, we used a tissue micro-array (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL). Methods: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation. Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined. Results: Our results identify two subgroups of lymphomas. The first group showed staining with bcl-6 and had an overall survival of 176 months (P=0.003). The majority of this group was negative for MUM1. The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1. Three of four patients with PCLBCL of the leg showed no staining with bcl-6. Conclusions: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival.展开更多
文摘目的探讨弥漫大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中活化的B细胞相关蛋白MUM1的表达与临床病理特征之间的关系。方法利用组织微阵列免疫组化检测60例DLBCL石蜡包埋组织中MUM1、bcl-6和CD10的表达。结果60例DLBCL被分为两种抗原表达表型:一种为活化的B细胞表型(A型)表达MUM1;另一种为生发中心B细胞表型(B型),表达CD10和(或)bcl-6但不表达MUM1。60例DLBCL中61.67%为A型,31.67%为B型,其中59.25%中心母细胞型,3/4免疫母细胞型,2/2间变性大B细胞型均为A型。A型在结外和结内DLBCL中分别占61.76%和61.54%,而在胃肠道DLBCL中的比例(47%)显著低于在其他结外DLBCL中的比例(80%,P=0.079)。在MUM-1(+)/bcl-6(+)/CD10(+/-)的病例中,75.00%(12/16)为结外DLBCL,高于在MUM-1(+)/bcl-6(-)/CD10(-)病例中的比例43.75%(7/16),但差异没有显著性(P=0.149)。结论A型(表达MUM1)在DLBCL中的比例较高,提示MUM1表达很可能与DLBCL组织学变异有关,联合检测CD10和bcl-6,可协助DLBCL分型诊断。
文摘目的探讨bcl-2、bcl-6、CD10、MUM1在弥漫性大B细胞淋巴瘤(diffuse large B-cell lymphoma,DLBCL)中的表达及与亚分类的关系。方法应用免疫组织化学S-P法,检测60例弥漫性大B细胞淋巴瘤标本中bcl-2、bcl-6、CD10、MUM1蛋白的表达水平。结果bcl-2、bcl-6、CD10、MUM1在60例弥漫性大B细胞淋巴瘤中的表达率分别为55.0%(33/60)、48.3%(29/60)、46.7%(28/60)、58.3%(35/60),其中GCB占55.0%(33/60),non-GCB占45.0%(27/60)。GCB、non-GCB中bcl-2的表达差异具有显著性。在non-GCB中,bcl-6+与bcl-6-的病例bcl-2表达的差异具有显著性。结论该组病例GCB所占的比率超过non-GCB,bcl-2在DLBCL亚分类中可能具有一定的作用。
文摘弥漫大B细胞淋巴瘤（diffused large B cell lym-plaoma,DLBCL）是非霍奇金淋巴瘤（NHL）中最大的一个亚群,是成人最常见的NHL[1],约占NHL总数的30%～40%[2].在WHO关于淋巴系统肿瘤的分类[3]中,DLBCL被定义为：B细胞起源的,有大的肿瘤细胞,具有侵袭性临床表现,需要高效力化疗的一组恶性淋巴瘤,这类肿瘤发生于淋巴结内或结外,可原发或继发于其他低度恶性淋巴瘤的演进[4].
文摘Background: Systemic B-cell lymphomas have been studied using microarrays, which has led to a better understanding of their molecular characteristics. Initial microarray studies of these lymphomas have implicated several genes as important predictors of outcome. In this study, we used a tissue micro-array (TMA) to characterize primary cutaneous large B-cell lymphomas (PCLBCL). Methods: We studied 14 patients for whom clinical follow up was available, including four patients whose lesions were limited to the leg on presentation. Immunohistochemical staining with CD20, CD44, CD21, CD5, CD10, bcl-2, bcl-6, Ki67, p53, and multiple myeloma 1 (MUM1) was examined. Results: Our results identify two subgroups of lymphomas. The first group showed staining with bcl-6 and had an overall survival of 176 months (P=0.003). The majority of this group was negative for MUM1. The second group lacked staining with bcl-6 and had an overall survival of 26 months, with a majority of these cases staining with MUM1. Three of four patients with PCLBCL of the leg showed no staining with bcl-6. Conclusions: Our study demonstrates the utility of TMAs in the analysis of PCLBCL and that expression of bcl-6 and MUM1 correlates with survival.
